platelet-activating factor (paf)

48740 RP (RP 55779) is an antagonist of platelet-activating factor.

PAF (C16) is a potent MAPK and MEK/ERK activator that induces increased vascular permeability. PAF (C16) (PAF (C16)) is a platelet-activating factor, a phospholipid-derived mediator and a ligand for PAF G protein-coupled receptor (PAFR). PAF (C16) has shown anti-apoptotic and anti-inflammatory activity in vitro, inhibiting Caspase-dependent apoptosis by interacting with its receptor (PAF-R) to perform cell signaling.

Aglafoline inhibits in a concentration-dependent manner the aggregation and ATP release reaction induced in washed rabbit platelets by PAF (platelet-activating factor). The IC50 values of Aglafoline on PAF (3.6 nM)-induced platelet aggregation were about 50 μM.

CP-96486 is a potent and orally active antagonist of leukotriene D4 (LTD4) and platelet activating factor (PAF) receptors, with inhibitory constants (Kis) of 20 and 24 nM, respectively.

PAF-AN-1 is a novel potent platelet-activating factor receptor (PAF) antagonist involved in the study of anaphylactic death.

Tulopafant (RP 59227) is a potent platelet-activating factor (PAF) antagonist that increases capillary patency and prolongs allograft heart survival.

CV-6209 is a potent antagonist of the platelet-activating factor (PAF) receptor.

DF-1111301 is a novel anti-allergic compound with anti-histamine H1 and anti-PAF activity.

(Rac)-Modipafantis an orally available and selective platelet-activating factor receptor (PAFR) antagonist that inhibits PAF-induced aggregation of washed platelets in rabbits, and can be used to study arthritis and ischemia/reperfusion (I/R) in the superior mesenteric artery (SMA) of the rat.

Rocepafant (LAU8080) is a platelet-activating factor (PAF) antagonist that attenuates hypoxic-ischemic brain damage in neonatal rats.Rocepafant inhibits tumor necrosis factor-Afa-mediated cytotoxicity in mouse L929 tumor cells.

SDZ-62-434, a platelet-activating factor inhibitor with antitumor activity, inhibits bombesin- and platelet-derived growth factor-induced DNA synthesis in quiescent Swiss 3T3 cells, making it a potential candidate for studying leukemia, human xenograft colorectal cancer, and lung cancer.

Dersalazine (Dersalazine Free Base), an inhibitor of platelet-activating factor, exerts intestinal anti-inflammatory activity in different rodent types of colitis by down-regulating IL-17 expression, with potential efficacy in patients with ulcerative colitis.

PAF C-18 is a naturally occurring phospholipid molecule belonging to the platelet-activating factor (PAF) family, which acts as an intercellular signaling molecule involved in platelet aggregation, vasodilatation, and inflammatory responses.PAF C-18 is involved in hemostasis and thrombosis by binding to its specific G-protein-coupled receptor (PAFR) and activating.

SCH-37370 is an effective and orally active dual antagonist of platelet-activating factor and histamine. Sch 37370 blocks the binding of [3H]pyrilamine to histamine-H1 receptors in rat brain membranes. Sch 37370 selectively inhibits PAF-induced aggregation of human platelets (IC50 : 0.6 mM) and also competes with PAF binding to specific sites in membrane preparations from human lungs (IC50 : 1.2 mM).

CMI-392 is a dual inhibitor of 5-lipoxygenase and a receptor antagonist for platelet-activating factor (PAF) with IC50 values of 100 nM and 10 nM, respectively.

TCV-309 chloride is an antagonist of platelet activating factor (PAF).

YM-264 is a selective and orally active antagonist of platelet-activating factor (PAF) (pKi value of 8.85 for rabbit platelet membranes).

(+)-Guaiacin, isolated from the bark of Machilus wangchiana Chun, demonstrates potent in vitro inhibition of β-glucuronidase release in rat polymorphonuclear leukocytes (PMNs) induced by platelet-activating factor (PAF).

Apafant (WEB 2086) is a highly potent platelet activating factor (PAF) antagonist that blocks eosinophil activation and can be used to study experimental allergic conjunctivitis in guinea pigs.

E-6123 is an antagonist of platelet-activating factor (PAF) receptor.

Foropafant (SR27417) is a highly potent and selective platelet-activating factor (PAF) receptor antagonist (Ki: 57 pM). Foropafant potently inhibits the PAF-induced aggregation of rabbit and human platelets.

Ro-24-0238 is an antagonist of platelet-activating factor and an inhibitor of thromboxane synthesis, used for reducing inflammation and damage caused by local release of PAF [platelet-activating factor].

ST-899 is an innovative platelet-activating factor (PAF) receptor antagonist. It significantly reduces the mortality rate in mice experiencing shock induced by endotoxins (LPS). The compound markedly inhibits the LPS-induced increase in serum tumor necrosis factor (TNF) levels while leaving interleukin-6 (IL-6) unaffected. The mechanism by which ST-899 operates involves disrupting the positive feedback loop between PAF and TNF, thereby mitigating inflammatory responses. ST-899 is applicable for studies related to inflammatory diseases such as septic shock.

P11 is a selective platelet-activating factor acetylhydrolase (PAFAH1b2 and PAFAH1b3) inhibitor, blocking PAFAH1b2/3-mediated hydrolysis of PAF to lysophosphatidic acid, used to study PAFAH1b2/3 cellular functions.